Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
7.15% | 6.88% | 7.15% | 8.92% | |
| (17.19%) | (17.77%) | (20.69%) | (27.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(22.29%) | (22.91%) | (27.44%) | (37.72%) | |
Average Days of Receivables |
0.00 | 460.64 | 423.71 | 426.58 | |
Free Cash Flow per Share |
(1.09) | (0.87) | (0.93) | (0.76) | |
Free Cash Flow |
(146.73) | (117.10) | (131.84) | (141.52) | |
Capital Expenditures |
(34.95) | 3.02 | 0.37 | (0.35) | |
| Other line items | |||||
Cash ROIC |
19.93% | 15.80% | 16.50% | 20.16% | |
Accounts Receivable Turnover |
0.00 | 0.50 | 0.64 | 0.60 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.02 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 12,779.73% | 13,577.28% | 16,004.28% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 5,798.10% | 5,482.45% | 5,760.27% | |
Share Based Compensation of Revenue |
0.00% | 2,837.18% | 2,684.48% | 2,801.71% | |
Interest Coverage |
(24,458.14) | (27,501.17) | (8,871.16) | (9,327.16) | |
Operating CF/Net income |
1.57 | 1.74 | 1.83 | 1.68 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.12 | 0.12 | |
Capex/Depreciation |
(5.54) | 0.46 | 0.06 | (0.05) | |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.00 | |
Operating CF per Share |
(0.83) | (0.90) | (0.93) | (0.76) | |
Capex per Share |
(0.26) | 0.02 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (3.38) | (0.42) | 0.43 |
Columns are period end dates